203715 Sigma-AldrichBQ-610 - Calbiochem
A highly selective ETA receptor antagonist (IC₅₀ = 20 nM) that attenuates ET-induced reduction in cardiac output.
More>> A highly selective ETA receptor antagonist (IC₅₀ = 20 nM) that attenuates ET-induced reduction in cardiac output. Less<<Productos recomendados
Descripción
Replacement Information |
---|
Tabla espec. clave
Empirical Formula |
---|
C₃₆H₄₇N₇O₆ |
Description | |
---|---|
Overview | This product has been discontinued. A highly selective ETA receptor antagonist (IC50 = 20 nM) that attenuates ET-induced reduction in cardiac output. Also inhibits ET-1- and ET-3-induced activation of adenylate cyclase (IC50 = 28.2 nM). BQ-610 is 30-fold more potent than BQ-123 (Cat. No. 05-23-3831) in porcine aortic smooth muscle membrane assay. |
Catalogue Number | 203715 |
Brand Family | Calbiochem® |
Product Information | |
---|---|
ATP Competitive | N |
Form | White lyophilized powder |
Formulation | Supplied as an ammonium salt. |
Hill Formula | C₃₆H₄₇N₇O₆ |
Chemical formula | C₃₆H₄₇N₇O₆ |
Hygroscopic | Hygroscopic |
Reversible | N |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | ETA receptor antagonist |
Primary Target IC<sub>50</sub> | 20 nM as ETA receptor antagonist that attenuates ET-induced reduction in cardiac output |
Purity | ≥90% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | N |
Peptide Sequence | Homopiperidinyl-CO-Leu-D-Trp(CHO)-D-Trp-ONH4 |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information |
---|
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Número de referencia | GTIN |
203715 | 0 |
Documentation
BQ-610 - Calbiochem Ficha datos de seguridad (MSDS)
Título |
---|
BQ-610 - Calbiochem Certificados de análisis
Cargo | Número de lote |
---|---|
203715 |
Referencias bibliográficas
Visión general referencias |
---|
Beyer, M.E., et al. 1999. Hypertension 33, 145. Carratu, P., et al. 1997. Am. J. Physiol. 272, L1021. Illing, B., et al. 1996. J. Cardiovasc. Pharmacol. 27, 487. Han, H., et al. 1995. J. Mol. Cell. Cardiol. 27, 761. Ishikawa, K., et al. 1992. in Peptides, Schneider and Eberle, eds. (ESCOM), p. 685. |